pageleftimg products
pagebanner products
imgfollow

ABV-1505  Attention Deficit Hyperactivity Disorder 

▌ Indication
    Attention Deficit Hyperactivity Disorder (ADHD)

▌ MOA
    Norepinephrine Transporter (NET) inhibitor
img 1505-1

▌ Status
    Q1, 2016 IND approval for phase II trial from US FDA, TFDA.

▌ Patent
    Granted in US, GB, JP, DE, FR, IT, CH, TW

 

▌ Toxicology
    Genotoxicity: negative
    NOAEL in rats & dogs: 3000mg/kg/day

▌ Phase I
    Genotoxicity: negative
    NOAEL in rats & dogs: 3000mg/kg/day

▌ Phase I
    Well-tolerated in healthy volunteers up to 3800 mg (single dose)

Copyright © American BriVision Corporation . All rights reserved. Design BY NOYAINC